Class III devices do not warrant annual payment update

March 13, 2006

The Government Accountability Office is recommending that Congress consider establishing a uniform payment update to the DME fee schedule for 2008 for class II and III DME devices. GAO conducted a study and found that manufacturers of class III devices, with limited exceptions, have higher premarketing costs than manufacturers of class II devices that are similar to class III devices.

Class III devices do not warrant annual payment update

The Government Accountability Office is recommending that Congress consider establishing a uniform payment update to the DME fee schedule for 2008 for class II and III DME devices. GAO conducted a study and found that manufacturers of class III devices, with limited exceptions, have higher premarketing costs than manufacturers of class II devices that are similar to class III devices. Premarketing costs consist of FDA user fees and research and development costs.

To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.